The specific objective of this grant continuation application is to provide for Mayo Clinic's continued participation in the Eastern Cooperative Oncology Group activities directed at a greater understanding of cancer and cancer related problems and the development of improved cancer treatment programs and cancer patient survival. Group activities of major importance continue to include the development of improved diagnostic procedures, the study of new cancer chemotherapy agents, and the identification of the value of combined modality therapy and new treatment regimens. Emphasis as before will be placed on direct patient care in a predominant out patient clinic setting. Continued interest and participation in Group activities relate to epidemiologic studies, natural history, and biologic patterns of specific neoplasms will be provided as possible. With the addition of new patient resources in the expansion of the Mayo medical practice and continuing NCCTG activities we would anticipate that we would exceed our previous protocol entry and scientific contribution. We would hope to continue to participate in disease specific committee activities, the evaluation of new protocol design and treatment regimens and such administrative roles as might be appointed and appropriate. This ECOG affiliation and the treatment programs which have evolved, provide major benefits to Mayo, its investigators, the members of NCCTG, their regional cancer programs, and the large group of cancer patients who are involved in these research activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA013650-18
Application #
3556221
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-06-01
Project End
1994-04-30
Budget Start
1990-05-01
Budget End
1991-04-30
Support Year
18
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Ailawadhi, Sikander; Jacobus, Susanna; Sexton, Rachael et al. (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8:67
Partridge, Ann H; Sepucha, Karen; O'Neill, Anne et al. (2017) Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy? Breast Cancer Res Treat 165:545-553
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Pine, Alexander B; Lee, Eun-Ju; Sekeres, Mikkael et al. (2017) Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion 57:289-295
Vaz-Luis, Ines; O'Neill, Anne; Sepucha, Karen et al. (2017) Survival benefit needed to undergo chemotherapy: Patient and physician preferences. Cancer 123:2821-2828
Roberts, Kathryn G; Gu, Zhaohui; Payne-Turner, Debbie et al. (2017) High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol 35:394-401
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Barta, Stefan K; Li, Hailun; Hochster, Howard S et al. (2016) Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer 122:2996-3004

Showing the most recent 10 out of 159 publications